SWOG/NCI phase II dual anti-CTLA-4/PD-1 blockade in rare tumors: nonepithelial ovarian cancer 2024

ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b/2 study 2022